Reported number of events for modeling
| Variable . | No IFN . | IFN . |
|---|---|---|
| Deaths, N (%) | 128 (51) | 235 (48) |
| Nonrelapse mortality, N (%) | 111 (45) | 216 (44) |
| Failure to engraft, N (%) | 14 (6) | 32 (7) |
| Hematologic relapses, N (%) | 18 (7) | 37 (8) |
| Acute GVHD, N (%) | 194 (78) | 386 (79) |
| Maximum grade acute GVHD, % | ||
| I | 25 | 29 |
| II | 30 | 36 |
| III | 26 | 20 |
| IV | 20 | 16 |
| Chronic GVHD, N (%) | 121 (49) | 226 (47) |
| Maximum grade chronic GVHD, % | ||
| Limited | 31 | 35 |
| Extensive | 69 | 65 |
| Variable . | No IFN . | IFN . |
|---|---|---|
| Deaths, N (%) | 128 (51) | 235 (48) |
| Nonrelapse mortality, N (%) | 111 (45) | 216 (44) |
| Failure to engraft, N (%) | 14 (6) | 32 (7) |
| Hematologic relapses, N (%) | 18 (7) | 37 (8) |
| Acute GVHD, N (%) | 194 (78) | 386 (79) |
| Maximum grade acute GVHD, % | ||
| I | 25 | 29 |
| II | 30 | 36 |
| III | 26 | 20 |
| IV | 20 | 16 |
| Chronic GVHD, N (%) | 121 (49) | 226 (47) |
| Maximum grade chronic GVHD, % | ||
| Limited | 31 | 35 |
| Extensive | 69 | 65 |